Consistently, our findings on ovarian cancer reveal higher prevalences of BRCA1 and BRCA2 mutations in subtypes 1 and 3, which are associated with better survival and responses to treatments compared to subtype 2 (Figure 6c). This evidence concerns the gene BRCA2 and ovarian cancer.